How it unfolded
As of April 2026, UnitedHealth Group (UNH) has been experiencing a challenging period in the stock market. Just before the anticipated earnings report on April 21, 2026, the company’s stock price stood at $277.17, reflecting a significant drop of 22.7% over the past six months. This decline has raised questions among investors about the future performance of the stock and the overall health of the company.
UnitedHealth, which operates both a health insurance business and Optum, a healthcare services division, reported a revenue of $447.6 billion over the past 12 months. Despite this substantial revenue figure, the company’s earnings per share (EPS) growth has stalled over the last five years, leading to increased scrutiny from analysts and investors alike. Wall Street is now expecting an EPS of $6.69 for the first quarter of 2026, which represents an 8% decrease year-over-year.
On the day of the earnings report, analysts from Raymond James upgraded UNH to an Outperform rating, setting a price target of $330. Following this upgrade, the stock rose approximately 1.2%, indicating a slight positive reaction from the market. John Ransom from Raymond James commented, “Wall Street is underestimating the company’s earnings power, particularly around cost savings,” suggesting that there may be more potential for growth than currently reflected in the stock price.
Historically, UnitedHealth has demonstrated resilience, with a five-year average return on invested capital (ROIC) of 19.6%. However, the recent performance has raised concerns among investors. The last quarterly earnings report saw UnitedHealth beating expectations with an EPS of $2.11 compared to the consensus of $2.09, yet the overall trend of declining EPS growth remains a point of concern.
In addition to the earnings report, investors are also keeping a close eye on the company’s dividend policy. UnitedHealth pays an annualized dividend of $8.84 per share, yielding around 3.2%. This consistent dividend payout may provide some reassurance to investors looking for income amidst the stock’s volatility.
Institutional ownership of UnitedHealth is approximately 87.9% of the float, indicating a strong interest from large investors. However, not everyone is fully convinced about the stock’s potential. The broader Wall Street picture on UNH remains constructive, but uncertainties linger regarding the impact of RADV audits on the company’s business and a pending Ninth Circuit ruling that could expand legal liability if the decision goes against UnitedHealth. Details remain unconfirmed.
As the earnings report approaches, the market will be closely watching how UnitedHealth navigates these challenges and whether it can regain investor confidence. The outcome of the upcoming earnings report will be crucial in determining the stock’s trajectory in the coming months.
